| Symbol | BNTC |
|---|---|
| Name | BENITEC BIOPHARMA INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 3940 TRUST WAY, HAYWARD, California, 94545, United States |
| Telephone | +1 510 780-0819 |
| Fax | — |
| — | |
| Website | https://www.benitec.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001808898 |
| Description | Benitec Biopharma Inc is a biotechnology company developing a proprietary therapeutic technology platform that combines RNA interference with gene therapy for providing sustained, long-lasting silencing of disease-causing genes from a single administration. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The company is developing product candidates in chronic and life-threatening human disease areas including Orphan disease: Oculopharyngeal Muscular Dystrophy (OPMD) and Infectious disease: Hepatitis B Virus (HBV). Additional info from NASDAQ: |
(99% Neutral) BENITEC BIOPHARMA INC. (BNTC) Announces New Board Appointment
Read moreFriedman David Matthew 🟢 acquired 35.0K shares (1 derivative) of Benitec Biopharma Inc. (BNTC) at $11.45 Transaction Date: May 26, 2026 | Filing ID: 245918
Read moreNew Form 3 - Benitec Biopharma Inc. <b>Filed:</b> 2026-05-28 <b>AccNo:</b> 0001193125-26-245915 <b>Size:</b> 2 KB
Read more(19% Negative) BENITEC BIOPHARMA INC. (BNTC) Reports Q2 2026 Financial Results
Read moreBenitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational Update
Read moreBenitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational Update
Read moreBenitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the 2026 American Society of Gene and Cell Therapy Annual Meeting
Read moreBenitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the 2026 American Society of Gene and Cell Therapy Annual Meeting
Read moreSeaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr. Sharon Mates, to its Board of Directors
Read moreBenitec Biopharma to Host Industry Forum Breakfast Event at the2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, the Only Clinical-Stage Therapeutic in Development for Oculopharyngeal Muscular Dystrophy (OPMD)
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06185673 | A Study to Evaluate the Safety and Clinical Activity of Intramuscular Doses of … | Phase1 | Oculopharyngeal Muscular Dystrophy | Recruiting | 2023-11-28 | 2040-11-01 | ClinicalTrials.gov |
| NCT03433027 | A Study of BB-401 in Recurrent or Metastatic Head and Neck Squamous Cell Carcin… | Phase2 | Head and Neck Squamous Cell Carcinoma | Completed | 2018-03-15 | 2020-04-06 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| BB-401 | Other | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma | COMPLETED | NCT03433027 |
| BB-301: Dose expansion phase 2a | Other | Phase PHASE1 | Oculopharyngeal Muscular Dystrophy | RECRUITING | NCT06185673 |
| BB-301: Dose escalation phase 1b cohort 3 | Other | Phase PHASE1 | Oculopharyngeal Muscular Dystrophy | RECRUITING | NCT06185673 |
| BB-301: Dose escalation phase 1b cohort 2 | Other | Phase PHASE1 | Oculopharyngeal Muscular Dystrophy | RECRUITING | NCT06185673 |
| BB-301: Dose escalation phase 1b cohort 1 | Other | Phase PHASE1 | Oculopharyngeal Muscular Dystrophy | RECRUITING | NCT06185673 |
| BB-301: Dose expansion phase 2a | GENETIC | Phase PHASE1 | Oculopharyngeal Muscular Dystrophy | RECRUITING | NCT06185673 |
| BB-301: Dose escalation phase 1b cohort 3 | GENETIC | Phase PHASE1 | Oculopharyngeal Muscular Dystrophy | RECRUITING | NCT06185673 |
| BB-301: Dose escalation phase 1b cohort 2 | GENETIC | Phase PHASE1 | Oculopharyngeal Muscular Dystrophy | RECRUITING | NCT06185673 |
| BB-301: Dose escalation phase 1b cohort 1 | GENETIC | Phase PHASE1 | Oculopharyngeal Muscular Dystrophy | RECRUITING | NCT06185673 |
| BB-401 | DRUG | Phase PHASE2 | Head and Neck Squamous Cell Carcinoma | COMPLETED | NCT03433027 |